Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-9758495-B2
Application number	US-201414774645-A
Country	US
Kind code	B2
Filing date	Mar 13, 2014
Priority date	Mar 14, 2013
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).

First claim

What is claimed is:

1. A compound of Formula I, or a pharmaceutically acceptable salt thereof,

wherein:
X is S(═O) 2 or —S(═O) 2 N(R a )—;
Z is C 1-6 alkyl or C 3-6 cyclolalkyl;
A is a 5 or 6 membered heteroaryl group containing a nitrogen atom, or an N-oxide thereof, and from 0 to 2 additional heteroatoms independently selected from O, N, or S, where the heteroaryl group may be unsubstituted or substituted with from 1 to 3 substituents independently selected from, halo, C 1-6 alkyl, —OC 1-6 alkyl, —OCF 3 , —CF 3 ,
—CHF 2 or —CH 2 F;
R 1 is hydrogen or C 1-6 alkyl, where the alkyl group can be unsubstituted or substituted with from 1 to 3 substituents independently selected from halo, —OH, —OC 1-6 alkyl,
—OCF 3 , —CF 3 , —CN, —CHF 2 or —CH 2 F;
R 2 is hydrogen or C 1-6 alkyl;
R 3 is C 3-6 cycloalkyl or C 1-6 alkyl, where the cycloalkyl or alkyl group can be unsubstituted or substituted with from 1 to 2 substituents independently selected from halo, C 1-6 alkyl, —CH 2 CF 3 , —CF 3 , —OCF 3 , —CHF 2 or —CH 2 F;
R 4 is a phenyl or pyridyl group which is substituted with from one to three substituents independently selected from halo or C 1-6 alkyl;
R 5 is a phenyl or pyridyl group which is substituted with from one to three substituents independently selected from halo or C 1-6 alkyl;
n is 0, 1 or 2;
m is 1 or 2; and
R a is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl or phenyl, where the phenyl or cycloalkyl group is unsubstituted or substituted with from one to three halo groups.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is S(═O) 2 .

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —S(═O) 2 N(R a )—.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 2.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is C 1-6 alkyl.

8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —CH 3 .

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is C 1-6 alkyl.

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein R 2 is —CH 3 or —CH 2 CH 3 .

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is C 3-6 cycloalkyl or substituted C 3-6 cycloalkyl.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is C 1-6 alkyl or substituted C 1-6 alkyl.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is cyclopropyl.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is substituted phenyl.

16. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 4 is halo substituted phenyl.

17. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein R 4 is para-halo substituted phenyl.

18. The compound of claim 17 , or a pharmaceutically acceptable salt thereof, wherein R 4 is para-chloro substituted phenyl.

19. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is substituted phenyl.

20. The compound of claim 19 , or a pharmaceutically acceptable salt thereof, wherein R 5 is halo substituted phenyl.

21. The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein R 5 is meta-halo phenyl.

22. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein R 5 is meta-chloro phenyl.

23. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1.

24. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 0.

25. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is a 5 membered heteroaryl group.

26. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is a 6 membered heteroaryl group.

27. The compound of claim 26 , or a pharmaceutically acceptable salt thereof, wherein A is pyridyl.

28. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is pyridine-N-oxide.

29. The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein A is a thiazolyl group.

30. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a is hydrogen.

31. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a is C 1-6 alkyl.

32. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is S(═O) 2 ;
A is pyridyl or thiazolyl;
R 1 is C 1-6 alkyl or hydrogen;
R 2 is hydrogen or C 1-6 alkyl;
R 3 is C 3-6 cycloalkyl or C 1-6 alkyl;
R 4 is a phenyl or pyridyl group which is substituted with from one to three substituents independently selected from halo;
R 5 is a phenyl or pyridyl group which is substituted with from one to three substituents independently selected from halo; and
m is 1.

33. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is S(═O) 2 ;
A is

R 1 is —CH 3 or hydrogen;
R 2 is hydrogen;
R 3 is cyclopropyl;
R 4 is 4-chlorophenyl;
R 5 is 3-chlorophenyl; and
m is 1.

34. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from:
6-(((2S,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl)methyl)nicotinic acid;
6-(((2R,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl)methyl)nicotinic acid;
2-(((2R,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl)methyl)-5-carboxypyridine 1-oxide;
2-(((2S,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl)methyl)-5-carboxypyridine 1-oxide;
2-(((2R,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(4-chloro-3-fluorophenyl)-6-(3-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl)methyl)thiazole-5-carboxylic acid;
2-(((2S,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(4-chloro-3-fluorophenyl)-6-(3-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl)methyl)thiazole-5-carboxylic acid;
6-(((2R,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(4-chloro-3-fluorophenyl)-6-(3-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl)methyl)nicotinic acid; or
6-(((2S,5R,6R)-4-((S)-2-(tert-butylsulfonyl)-1-cyclo

Assignees

• Amgen Inc

Inventors

• Gonzalez Buenrostro Ana
• Li Yihong
• Medina Julio C
• Olson Steven H

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D413/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D417/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title